ReviewTranslational pediatrics2026
Probiotics in asthma: immunoregulatory mechanisms and emerging opportunities for respiratory delivery-a narrative review.
Review in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Asthma is a complex heterogeneous respiratory disease influenced by various factors such as genetics, immunity, and environment. Probiotics and related microbial preparations can be used in the prevention and treatment of asthma. This review aims to clarify the role and mechanism of microbial preparations in the treatment of asthma through respiratory administration, as well as the theoretical basis as delivery carriers. This may provide new insights for the prevention and treatment of asthma. Methods: This study employed the narrative review method and searched for articles published on PubMed between January 2007 and February 2026. The search terms included asthma, probiotics, airway microbiota, respiratory administration and nanoparticles. The inclusion criteria covered relevant original research, reviews, and guidelines, while editorials and articles lacking full text were excluded. Key Content and Findings: Alterations in airway microbiota are closely associated with the occurrence of asthma. Animal studies have demonstrated that oral intake of probiotics can effectively alleviate asthma symptoms, but their clinical application remains controversial. The main reasons include differences in study populations, asthma phenotypes, probiotic strains, dosages and treatment courses. The therapeutic effects and mechanisms of probiotic respiratory administration for asthma have been confirmed in animal experiments. Probiotics as delivery vehicles for respiratory administration in the treatment of asthma are theoretically feasible. Conclusions: Probiotics respiratory administration represents a potentially promising strategy to treat asthma. Probiotics as delivery vehicles can also be used to deliver anti-asthma drugs. However, current evidence is predominantly preclinical, and further studies are needed to optimize delivery, ensure safety and product standardization, and confirm clinical efficacy before routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.